Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy-Reference-Cited by-同舟云学术

Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy

Published:2015-05-28 Issue:7 Volume:6 Page:804-808
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Tosh Dilip K.¹,Crane Steven¹,Chen Zhoumou²,Paoletta Silvia¹,Gao Zhan-Guo¹,Gizewski Elizabeth³,Auchampach John A.³,Salvemini Daniela²,Jacobson Kenneth A.¹

Affiliation:

1. Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, United States

2. Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, Missouri 63104, United States

3. Department of Pharmacology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Cancer Institute

National Heart, Lung, and Blood Institute

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00150